Coblopasvir dihydrochloride is primarily used in the treatment of hepatitis C virus (HCV) infections. It functions as an NS5A inhibitor, disrupting viral replication by targeting the NS5A protein, which is essential for the HCV life cycle. This antiviral activity makes it a key component in combination therapies with other direct-acting antivirals, such as sofosbuvir or velpatasvir, to achieve high cure rates across multiple HCV genotypes. The compound is especially effective in both treatment-naïve patients and those who have failed prior therapies. Due to its potency and favorable safety profile, it contributes to shorter treatment durations and improved patient outcomes in chronic hepatitis C management.